• Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., said it completed patient enrollment in its pivotal Phase III NX02-0017 study testing NX-1207 in benign prostatic hyperplasia. Top-line results are expected in late 2013.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST